J&J Says CHMP Adopts Positive Opinion For Balversa (Erdafitinib) For Treatment Of Adult Patients
Johnson & Johnson +0.45% Pre
Johnson & Johnson JNJ | 161.60 161.60 | +0.45% 0.00% Pre |
- Reuters
J&J Says CHMP Adopts Positive Opinion For Balversa (Erdafitinib) For Treatment Of Adult Patients
Johnson & Johnson JNJ | 161.60 161.60 | +0.45% 0.00% Pre |
- Reuters